PD-L1-Targeting Nanoparticles for the Treatment of Triple-Negative Breast Cancer: A Preclinical Model.

Int J Mol Sci · 2025 · PMC11989481 · PMID 40244130

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The difference between the NIC and saline ( p = 0.0005) or STI-3031 ( p = 0.0008) was highly significant, while the difference between STI3031:PTX NIC and atezolizumab–PTX NIC was slightly less significant ( p = 0.0019).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.